Repligen (RGEN) Tops Q1 EPS by 5c, Lowers FY23 Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. MRK
7. LVS
8. SAP
9. CSX
10. LRCX

Go back to Repligen (RGEN) Tops Q1 EPS by 5c, Lowers FY23 Guidance

Repligen Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance

May 2, 2023 7:30 AM EDT

Reports first quarter revenue of $182.7 million, with base business growth of 4% as reported and 7% at constant currencyReports first quarter gross margin of 55.2% on both GAAP and adjusted (non-GAAP) basisClosed on acquisition of single-use bag manufacturer FlexBiosys Inc. in April

WALTHAM, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first fiscal quarter ended March 31, 2023. Provided in this press release are financial highlights for the quarter, updates to... More